A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
A Dose-escalation and Safety Study of CID-103 Followed by a Randomized, Open-label, Parallel-arm Multi-dose Study Evaluating the Efficacy and Tolerability of CID-103 in Adults With Chronic Immune Thrombocytopenia
The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP). The main questions the study aims to answer are:
- To evaluate the safety and tolerability of CID-103 in subjects with ITP with different increasing doses of CID-103.
- To further evaluate the safety and tolerability of CID-103 at two or three dose levels and to select an optimal dose and administration regimen for CID-103 for further study of clinical efficacy.
The study will be done in two parts:
Part A will test increasing doses of CID-103 to see how safe it is and how well people tolerate it. Researchers will also aim to find a safe dose range.
Part B will compare up to three different doses of CID-103 to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.
CID-103 is given through an intravenous (IV) infusion. During the study, participants may receive treatment for up to 6 months, followed by a post-treatment safety follow-up period to check for ongoing safety and effectiveness.This study is an important step toward developing a new treatment for people living with chronic ITP. If CID-103 is found to be safe and effective, it could offer a new option for patients who do not respond well to current therapies.
研究概览
详细说明
The enrollment of participants in part A has been completed (ClinicalTrials.gov ID: NCT07017725). Totally 23 participants have been enrolled. Three CID-103 doseages including 600mg, 900mg, and 1200mg have been proposed for part B for further evaluation.
This is Part B study, it will compare 600mg, 900mg, and 1200mg doses of CID-103 to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Aaron Yang
- 电话号码:+86 10 6561 8789
- 邮箱:aarony@casi.cn
研究联系人备份
- 姓名:Hao Zhang
- 电话号码:+86 10 6561 8789
- 邮箱:haoz@casi.cn
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100000
- Peking Union Medical College Hospital
-
接触:
- Tienan Zhu
- 电话号码:+86 10 69151188
- 邮箱:zhutn@pumch.cn
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510000
- Nanfang Hospital, Southern Medical University
-
接触:
- Jieyu Ye
- 电话号码:+86 20 61641888
- 邮箱:jieyu_ye@163.com
-
-
Hebei
-
Tangshan、Hebei、中国、063000
- North China University of Science and Technology Affiliated Hospital
-
-
Henan
-
Zhengzhou、Henan、中国、450000
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan、Hubei、中国、430000
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
接触:
- Heng Mei
- 电话号码:+86 27 85726114
- 邮箱:hmei@hust.edu.cn
-
-
Jiangsu
-
Suzhou、Jiangsu、中国、215000
- The First Affiliated Hospital of Soochow University
-
接触:
- Jie Yin
- 电话号码:+86 512 65223637
- 邮箱:yinjie@suda.edu.cn
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330000
- The First Affiliated Hospital of Nanchang University
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710000
- Shaanxi Provincial People's Hospital
-
接触:
- Yi Wang
- 电话号码:+86 29 85251331
- 邮箱:13571936193@163.com
-
-
Shandong
-
Jinan、Shandong、中国、50000
- Qilu Hospital of Shandong University
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300000
- Institute of Hematology & Blood Diseases Hospital, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
-
接触:
- Lei Zhang
- 电话号码:+86 22 23909999
- 邮箱:zhanglei1@ihcams.ac.cn
-
-
Yunnan
-
Kunming、Yunnan、中国、650000
- The Second Affiliated Hospital of Kunming Medical University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Male or female individuals aged 18 to 65 years at time of signing of ICF.
-
Diagnosed with ITP that has persisted for ≥ 3 months, diagnosed in accordance with The American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia or the Updated International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia (as locally applicable).
-
Diagnosis of ITP supported by a prior response to an ITP treatment (other than a thrombopoietin receptor agonists [TPO-RA]) that achieved a platelet count of ≥ 30 x 10^9/L and a doubling of baseline measurement.
-
Has received at least two lines of SOC systemic treatment (i.e., corticosteroids and one other agent).
Note: Subjects who have received one line of treatment and who are currently receiving a second line of treatment are also considered eligible Exceptions: Subjects who are intolerant of SOC treatment or subjects who do not have access to SOC treatment; approval from Medical Monitor is required.
-
Has a mean platelet count ≤ 35 x 10^9/L on at least two measurements at least one week apart during screening.
-
If receiving standard background treatment for ITP, treatment should be stable in dose and frequency for at least four weeks prior to first dose of CID-103.
Note: Permitted standard background treatments for ITP may include:
- one oral corticosteroid with or without up to two of the following
- one immunosuppressant from the following list: azathioprine, danazol, dapsone, cyclosporine, mycophenolate mofetil, mycophenolate sodium
- one TPO-RA (romiplostim, eltrombopag, avatrombopag) administered at standard therapeutic doses for at least four weeks
- fostamatinib.
-
Adequate organ function
-
Contraception: Female participants must either be non-pregnant or not breastfeeding and must have a negative pregnancy test. Male and female participants must meet the contraceptive requirements.
Exclusion Criteria:
-
Prior treatment with any anti-CD38 agent, or has been treated with anti-Bruton's tyrosine kinase (BTK), neonatal Fc receptor (FcRn) antagonist or complement inhibitor within three months prior to first dose of CID-103.
-
Use of intravenous (IV) immunoglobulin, subcutaneous immunoglobulin or anti-D immunoglobulin treatment within four weeks of screening.
-
IgG < 300 mg/dL
-
Use or expected immediate use of rescue therapy for an active hemorrhage, high risk of bleeding or critically low platelets within two weeks prior to first dose of CID-103.
-
More than a 10% variation in corticosteroid and/or TPO-RA dose within two weeks prior to first dose of CID-103
-
Treatment with rituximab or splenectomy within the three months prior to first dose of CID-103.
-
Use of anticoagulants or any drug with antiplatelet effect (such as aspirin) within three weeks before screening.
-
Immunosuppressant drugs other than corticosteroids and those outlined in inclusion criterion #6.
Note: These drugs should be discontinued for at least 14 days before first dose of CID-103.
-
Receiving other concurrent investigational therapies or have received investigational therapies within four weeks of the first dose of CID-103 or five half-lives (if shorter).
-
Active hemolytic anemia.
-
Diagnosed with severe chronic obstructive pulmonary disease (COPD), Global Initiative for Chronic Obstructive Lung Disease (GOLD Stage 3 or 4) or asthma, and a pre-bronchodilator forced expiratory volume in one second (FEV1) < 50% of predicted normal.
-
Has been diagnosed with myelodysplastic syndrome or other active malignancy.
-
Known / clinically significant amyloidosis.
-
Requires renal dialysis.
-
Has a history of any thrombotic or embolic event within six months before screening.
-
A history or evidence of cardiovascular risk including any of the following:
- Current left ventricular ejection fraction < 50%
- A history or evidence of current clinically significant uncontrolled ventricular arrhythmia. Subjects with atrial fibrillation controlled for > 30 days prior to first dose of CID-103 are eligible.
- A history of acute coronary syndrome (including myocardial infarction or unstable angina), coronary angioplasty or stenting within six months prior to first dose of CID-103
- A history or evidence of current ≥ Class III congestive heart failure as defined by the New York Heart Association (NYHA) guidelines
- Treatment refractory hypertension defined as a blood pressure of systolic > 160 mmHg and/or diastolic > 100 mmHg which cannot be controlled by anti-hypertensives.
-
History or clinical evidence of any surgical or medical condition which the Investigator judges as likely to interfere with the results of the study or pose an additional risk in participating, particularly any pre-existing condition that would put the subject at additional risk should they experience an IRR
-
Any unresolved treatment-related AE(s) from prior treatment that have not resolved to Grade 1 or baseline value prior to first dose of CID-103.
-
Active infection requiring systemic therapy.
-
Known hypersensitivity to CID-103 excipients or prior severe hypersensitivity to a monoclonal antibody.
-
History of severe recurrent or chronic infections, or acute infections requiring systemic treatment with antibiotics, antiviral drugs, antiparasitic drugs, anti-amoebic drugs, or antifungal drugs within four weeks prior to the first dose of CID-103 and during the screening period, or superficial skin infections requiring systemic treatment within one week prior to the first dose of CID-103.
-
History of known or suspected immunosuppression, including invasive opportunistic infections such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis pneumonia, and aspergillosis, even if the infection has resolved; or unusually frequent, recurrent, or prolonged infections (as judged by the Investigator).
-
Known active infection with human immunodeficiency virus (HIV) and CD4+ T cell count < 350/μL.
-
Known active infection with hepatitis B (HBV) (surface antigen) or infection with hepatitis C (HCV) in absence of sustained virologic response.
-
At the time of signing informed consent is a regular user (including "recreational / medical use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol). If a subject agrees to abstain for the duration of the study and is for a month prior to first dose of CID 103, they may be considered for enrollment in the trial at the discretion of the Investigator in agreement with the Medical Monitor.
-
Karnofsky Performance Status ≤ 70
-
Inability to perform study baseline RBC type and cross-match, phenotype (and genotype, if applicable) or lack of available baseline data on RBC phenotype (or genotype, if applicable).
-
Unable or not willing to agree to the evaluation of RBC antigens by phenotyping or genotyping.
-
Unable or not willing to sign the ICF and comply with the protocol and the restrictions and assessments therein.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:CID-103 1200mg
Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 1200mg administered. |
Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months. |
|
实验性的:CID-103 900mg
Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 900mg administered. |
Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months. |
|
实验性的:CID-103 600mg
Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 600mg administered. |
Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and tolerability of CID-103, Frequency of TEAEs
大体时间:10 months
|
Frequency of TEAEs |
10 months
|
|
Safety and tolerability of CID-103, Related AEs
大体时间:10 months
|
Related AEs |
10 months
|
|
Safety and tolerability of CID-103, Grade 3/4 AEs
大体时间:10 months
|
Grade 3/4 AEs |
10 months
|
|
Safety and tolerability of CID-103, Serious adverse events (SAEs)
大体时间:10 months
|
Serious adverse events (SAEs) |
10 months
|
|
Safety and tolerability of CID-103, Fatal AEs
大体时间:10 months
|
Fatal AEs |
10 months
|
|
Safety and tolerability of CID-103, AEs leading to CID-103 discontinuation
大体时间:12 weeks
|
AEs leading to CID-103 discontinuation up to Week 12 |
12 weeks
|
|
Safety and tolerability of CID-103
大体时间:12 weeks
|
Percentage of participants with at least one treatment-related Grade ≥ 3 TEAE, SAE or AE leading to CID-103 discontinuation up to Week 12 |
12 weeks
|
|
Platelet response
大体时间:12 weeks
|
A platelet count ≥ 50 x 10^9/L and ≥ 20 x 10^9/L above baseline achieved on at least two consecutive measurements at least seven days apart. |
12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Platelet count
大体时间:12 weeks
|
The secondary efficacy endpoint is Platelet count, defined as platelet count ≥ 30 x 10^9/L and > 2-fold increase in platelet count from baseline and absence of bleeding requiring medical intervention / treatment, measured on at least two consecutive occasions at least seven days apart. |
12 weeks
|
|
Complete platelet response
大体时间:12 weeks
|
The secondary efficacy endpoint includes percentage of participants with complete platelet response, defined as platelet count ≥ 100 x 10^9/L and absence of bleeding requiring medical intervention / treatment, measured on at least two consecutive occasions at least seven days apart. |
12 weeks
|
合作者和调查者
调查人员
- 学习椅:Junping Chen、CASI pharmaceuticals, Inc.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- XY2024067-EC-4
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.